John Jacob Ballroom I
The move from over-the-counter markets to the safety of clearing organizations is underway around the world. What impact does this have on established clearinghouses? Which characteristics of OTC products are transferrable to listed markets and which are not? How has the demand for more transparency, the discussion of what can be standardized and what cannot, and the debate over whether OTC products should be executed on exchanges played out in different jurisdictions?
Robert Urtheil, Partner, Corporate & Institutional Banking, Oliver Wyman
Jennifer Ilkiw, Director, Asia Pacific, IntercontinentalExchange
Ananda Radhakrishnan, Director of Clearing and Intermediary Oversight, Commodity Futures Trading Commission
Muthukrishnan Ramaswami, Senior Executive Vice President & Chief Operations Officer, Singapore Exchange
Brad Ridge, Director, Product Development Asia Pacific, ICAP
Derek Sammann, Managing Director, Financial Products & Services, CME Group